OBJECTIVE: The aim of this study was to identify gene variants of DAT1 (SLC6A3) that modulate subjective responses to acute cocaine exposure. METHODS:Non-treatment-seeking volunteers (n=66) with cocaine use disorders received a single bolus infusion of saline and cocaine (40 mg, intravenous) in a randomized order. Subjective effects were assessed with visual analog scales administered before (-15 min) and up to 20 min after infusion. Ratings of subjective effects were normalized to baseline, and saline infusion values were subtracted. Data were analyzed using repeated measures analysis of variance. DNA from the participants was genotyped for the DAT1 intron 8 (rs3836790) and 3'-untranslated region (rs28363170) variable number of tandem repeats. RESULTS:Participants were mostly male (∼80%) and African American (∼70%). No differences were found among drug use variables between groups for either polymorphism. Carriers of the 9-allele of the DAT1 3'-untranslated region (9,9 and 9,10) exhibited greater responses to cocaine for 'high', 'any drug effect', 'anxious', and 'stimulated' (all P-values<0.001) compared with individuals homozygous for the 10-allele. For the intron 8 polymorphism, individuals homozygous for the 6-allele exhibited greater responses for 'anxious' compared with carriers of the 5-allele (P<0.001). Individuals possessing the genotype pattern of 10,10 and at least one 5-allele reported lower responses to 'good effects', 'bad effects', 'depressed', and 'anxious' (all P-values<0.01). CONCLUSION: The data presented here show for the first time support for the hypothesis that genetic differences in DAT1 contribute to the variation in subjective responses to cocaine among participants with cocaine use disorders.
RCT Entities:
OBJECTIVE: The aim of this study was to identify gene variants of DAT1 (SLC6A3) that modulate subjective responses to acute cocaine exposure. METHODS: Non-treatment-seeking volunteers (n=66) with cocaine use disorders received a single bolus infusion of saline and cocaine (40 mg, intravenous) in a randomized order. Subjective effects were assessed with visual analog scales administered before (-15 min) and up to 20 min after infusion. Ratings of subjective effects were normalized to baseline, and saline infusion values were subtracted. Data were analyzed using repeated measures analysis of variance. DNA from the participants was genotyped for the DAT1 intron 8 (rs3836790) and 3'-untranslated region (rs28363170) variable number of tandem repeats. RESULTS:Participants were mostly male (∼80%) and African American (∼70%). No differences were found among drug use variables between groups for either polymorphism. Carriers of the 9-allele of the DAT1 3'-untranslated region (9,9 and 9,10) exhibited greater responses to cocaine for 'high', 'any drug effect', 'anxious', and 'stimulated' (all P-values<0.001) compared with individuals homozygous for the 10-allele. For the intron 8 polymorphism, individuals homozygous for the 6-allele exhibited greater responses for 'anxious' compared with carriers of the 5-allele (P<0.001). Individuals possessing the genotype pattern of 10,10 and at least one 5-allele reported lower responses to 'good effects', 'bad effects', 'depressed', and 'anxious' (all P-values<0.01). CONCLUSION: The data presented here show for the first time support for the hypothesis that genetic differences in DAT1 contribute to the variation in subjective responses to cocaine among participants with cocaine use disorders.
Authors: James J Mahoney; Ari D Kalechstein; Richard De La Garza; Thomas F Newton Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-01-31 Impact factor: 5.067
Authors: D Martinez; J Gelernter; A Abi-Dargham; C H van Dyck; L Kegeles; R B Innis; M Laruelle Journal: Neuropsychopharmacology Date: 2001-05 Impact factor: 7.853
Authors: Keeley J Brookes; Benjamin M Neale; Karen Sugden; Nadeem Khan; Philip Asherson; Ursula M D'Souza Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-12-05 Impact factor: 3.568
Authors: Teresa R Franklin; Falk W Lohoff; Ze Wang; Nathan Sciortino; Derek Harper; Yin Li; Will Jens; Jeffrey Cruz; Kyle Kampman; Ron Ehrman; Wade Berrettini; John A Detre; Charles P O'Brien; Anna Rose Childress Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Jean-Claude Dreher; Philip Kohn; Bhaskar Kolachana; Daniel R Weinberger; Karen Faith Berman Journal: Proc Natl Acad Sci U S A Date: 2008-12-22 Impact factor: 11.205
Authors: Camila Guindalini; Mark Howard; Kate Haddley; Ronaldo Laranjeira; David Collier; Nik Ammar; Ian Craig; Colin O'Gara; Vivian J Bubb; Tiffany Greenwood; John Kelsoe; Phil Asherson; Robin M Murray; Adauto Castelo; John P Quinn; Homero Vallada; Gerome Breen Journal: Proc Natl Acad Sci U S A Date: 2006-03-14 Impact factor: 11.205
Authors: Shabnam Azadeh; Brian P Hobbs; Liangsuo Ma; David A Nielsen; F Gerard Moeller; Veerabhadran Baladandayuthapani Journal: Neuroimage Date: 2015-10-17 Impact factor: 6.556
Authors: Michelle A Patriquin; Sara C Hamon; Mark J Harding; Ellen M Nielsen; Thomas F Newton; Richard De La Garza; David A Nielsen Journal: Psychiatr Genet Date: 2017-10 Impact factor: 2.458
Authors: June P Kampangkaew; Catherine J Spellicy; Ellen M Nielsen; Mark J Harding; An Ye; Sara C Hamon; Thomas R Kosten; David A Nielsen Journal: Am J Addict Date: 2019-05-14
Authors: Riley B Longtain; David P Graham; Mark J Harding; Richard De La Garza Ii; David A Nielsen Journal: Behav Brain Res Date: 2021-11-16 Impact factor: 3.332
Authors: Daryl Shorter; David A Nielsen; Sara C Hamon; Ellen M Nielsen; Thomas R Kosten; Thomas F Newton; Richard De La Garza Journal: Pharmacogenet Genomics Date: 2016-09 Impact factor: 2.089
Authors: Rebekka Schröder; Martin Reuter; Kaja Faßbender; Thomas Plieger; Jessie Poulsen; Simon S Y Lui; Raymond C K Chan; Ulrich Ettinger Journal: Psychopharmacology (Berl) Date: 2021-12-02 Impact factor: 4.530
Authors: Mark Moran; Kenneth Blum; Jessica Valdez Ponce; Lisa Lott; Marjorie C Gondré-Lewis; Sampada Badgaiyan; Raymond Brewer; B William Downs; Philip Fynman; Alexander Weingarten; Jean Lud Cadet; David E Smith; David Baron; Panayotis K Thanos; Edward J Modestino; Rajendra D Badgaiyan; Igor Elman; Mark S Gold Journal: Mol Neurobiol Date: 2021-03-08 Impact factor: 5.590